Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis(β-cyclodextrin)s:: solubilization and antitumor activity

被引:50
作者
Liu, Y [1 ]
Chen, GS
Chen, Y
Cao, DX
Ge, ZQ
Yuan, YJ
机构
[1] Nankai Univ, Dept Chem, State Key Lab Elementoorgan Chem, Tianjin 300071, Peoples R China
[2] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
基金
中国国家自然科学基金;
关键词
paclitaxel; cyclodextrin; inclusion complex; antitumor activity;
D O I
10.1016/j.bmc.2004.08.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The inclusion complexation behavior of paclitaxel with a series of oligo(ethylenediamino) bridged bis(beta-cyclodextrin)s possessing bridge chains in different length (1-4) has been investigated in order to improve the water solubility of paclitaxel. It is found that only the long-tethered bis(beta-cyclodextrin)s 1 and 2 can form the inclusion complexes with paclitaxel, which are characterized by NMR, SEM, XRD, FT-IR, TG-DTA, DSC, and microcalorimetry technology. The results obtained show that bis(beta-cyclodextrin)s 1 and 2 are able to solubilize paclitaxel to high levels up to 2 and 0.9 mg/mL, respectively. The high complex stability of bis(beta-cyclodextrin) 1 and paclitaxel is discussed from thermodynamic viewpoint. Furthermore, the cytotoxicity of these complexes assessed using a human erythroleukemia K562 cell line indicates that the IC50 value of 1/paclitaxel complex is 6.0 x 10(-10) mol/dm(3) (calculated as paclitaxel molar concentration), which means that the antitumor activity of 1/paclitaxel complex is better than that of parent paclitaxel (IC50 value 9.8 x 10(-10) mol/dm(3)). This high antitumor activity, along with the satisfactory water solubility and high thermal stability of the 1/paclitaxel complex, will be potentially useful for its clinical application as a highly effective antitumor drug. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5767 / 5775
页数:9
相关论文
共 44 条
[1]   Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships [J].
Adam, JM ;
Bennett, DJ ;
Bom, A ;
Clark, JK ;
Feilden, H ;
Hutchinson, EJ ;
Palin, R ;
Prosser, A ;
Rees, DC ;
Rosair, GM ;
Stevenson, D ;
Tarver, GJ ;
Zhang, MQ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) :1806-1816
[2]   Synthesis and antitumor activity of novel C-7 paclitaxel ethers: Discovery of BMS-184476 [J].
Altstadt, TJ ;
Fairchild, CR ;
Golik, J ;
Johnston, KA ;
Kadow, JF ;
Lee, FY ;
Long, BH ;
Rose, WC ;
Vyas, DM ;
Wong, H ;
Wu, MJ ;
Wittman, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (26) :4577-4583
[3]   Cyclodextrin dimers as cleavable carriers of photodynamic sensitizers [J].
Baugh, SDP ;
Yang, ZW ;
Leung, DK ;
Wilson, DM ;
Breslow, R .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (50) :12488-12494
[4]  
Baussanne I, 2001, CHEMBIOCHEM, V2, P777, DOI 10.1002/1439-7633(20011001)2:10<777::AID-CBIC777>3.0.CO
[5]  
2-C
[6]   TOPOGRAPHY OF CYCLODEXTRIN INCLUSION COMPLEXES .20. CIRCULAR AND FLIP-FLOP HYDROGEN-BONDING IN BETA-CYCLODEXTRIN UNDECAHYDRATE - A NEUTRON-DIFFRACTION STUDY [J].
BETZEL, C ;
SAENGER, W ;
HINGERTY, BE ;
BROWN, GM .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (24) :7545-7557
[7]  
BODOR SN, 1991, Patent No. 5024998
[8]  
Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO
[9]  
2-W
[10]  
DAVIGNON JP, 1987, PRINCIPLES CHEMOTHER